BioNexus secures exclusive CogniAI licence for Malaysian healthcare AI
BioNexus Gene Lab Corp. (Nasdaq: BGLC) has signed a definitive agreement with Ruanyun Edai Technology Inc. (Nasdaq: RYET) for an exclusive ten-year licence to deploy RYET's CogniAI document intelligence platform across Malaysia's healthcare sector. The deal, signed on 5 October 2026, positions the Kuala Lumpur-based company to target the Malaysian government's RM1 billion public healthcare digitisation programme, which covers 150 hospitals and more than 2,000 health clinics nationwide.
The Malaysian Ministry of Health has committed to equipping all public hospitals and health facilities with electronic medical records by 2029. Its facilities recorded 68.2 million patient arrivals in 2023, according to ministry data tabled in Parliament. BioNexus intends to offer CogniAI-based applications that bring existing paper and scanned records into digital form to complement that broader infrastructure rollout. The company has not yet been awarded any government contract, and any public-sector revenue would depend on procurement outcomes.
Deal structure and technology
The licence consideration is structured to preserve BioNexus's cash position. Rather than a cash payment, BGLC will issue 410,000 common shares to RYET at a stated value of US$3.5 million, alongside a separate share exchange of 150,000 BGLC common shares for 500,000 RYET ordinary shares. RYET will receive a 10% royalty on defined technology receipts actually collected, with no minimum royalty or annual platform fee, meaning the licensor's returns are tied directly to BGLC's commercial success.
CogniAI recognises, classifies and extracts information from documents and records. RYET reported approximately US$1.73 million of contracted commercial activity for the platform on an unaudited basis as of June 2026, and announced a deployment to digitise highway engineering archives in Ningxia, China, in September 2026. Under the agreement, BioNexus will host, adapt and integrate the platform, develop and brand its own applications, and retain ownership of what it builds. Personal data must be hosted in Malaysia, with no access from RYET entities outside the country.
Chief executive Sam Tan said the agreement was designed so that "RYET is taking its licence consideration in our shares and a royalty only on what we collect, so it does well only if we do." RYET's chief executive Maggie Fu pointed to BioNexus's local market knowledge as the rationale for the partnership structure.
Market context and competitive landscape
The broader intelligent document processing market is projected by Grand View Research to reach approximately US$12.35 billion by 2030, growing at roughly 33% annually from 2025, according to figures cited by BioNexus. The company has not independently verified this estimate.
Southeast Asia's healthcare digitisation push is attracting a growing number of technology vendors, ranging from large enterprise software providers to smaller regional specialists. BioNexus is a relatively small-cap player by global standards, which makes its reliance on an exclusive territorial licence, rather than proprietary AI development, a pragmatic route to market. The company already holds investments in Ascension Innovation and Fidelion Diagnostics, and obtained exclusive ASEAN rights to the VitaGuard minimal residual disease platform in November 2025. The CogniAI licence represents a third strand of an AI and technology strategy that spans diagnostics, genomics and now document intelligence.
Closing remains subject to technology delivery by 4 December 2026, acceptance testing, satisfactory due diligence and required regulatory approvals. Either party may terminate if closing has not occurred by 31 March 2027. The agreement also grants BioNexus the right to extend the licence into other Malaysian industries by written notice, broadening the potential revenue opportunity beyond healthcare should its initial programme gain traction.